Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 5, 2003, Pages 584-588

  Ahmad, Sarfraz ^a,d   Peter Bacher, H ^a,b   Lassen, Michael R ^c   Hoppensteadt, Debra A ^a   Leitz, Helen ^a   Misselwitz, Frank ^a,b   Walenga, Jeanine M ^a   Fareed, Jawed ^a,e  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b Knoll AG   (Germany)

^c HILLERØD HOSPITAL   (Denmark)

^d FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; THROMBOCYTE FACTOR 4;

ACHILLES TENDON RUPTURE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMOBILIZATION; LEG FRACTURE; MAJOR CLINICAL STUDY; OPTICAL DENSITY; PLASTER CAST; PREVALENCE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION;

ADOLESCENT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY SPECIFICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN M; ORTHOPEDICS; PLATELET FACTOR 4; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 0038754852     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol. 1995;89: 431-439.
2. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med. 1995;332:1374-1376.
3. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79:1.
4. Cines DB. Heparin-induced thrombocytopenia and thrombosis. In: Hematology: ASH Education Program Book. Washington, DC: American Society of Hematology; 2001:295-305.
5. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95.
6. Amiral J, Marfaing-Koka A, Poncz M, Meyer D. The biological basis of immune heparin-induced thrombocytopenia. Platelets. 1998;9:77-91.
7. Fabris F, Ahmad S, Cella G, et al. Pathophysiology of heparin-induced thrombocytopenia: clinical and diagnostic implications - a review. Arch Pathol Lab Med. 2000;124:1657-1666.
8. Kelton JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232-3239.
9. Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open-heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med. 1996;128: 346-347.
10. Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96: 1703-1708.
11. Blank M, Shoenfeld Y, Tavor S, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol. 2002; 14:121-128.
12. Amiral A, Wolf M, Fischer A-M, Boyer-Neumann C, Vissac A-M, Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol. 1996;92:954-959.
13. Ahmad S, Walenga JM, Jeske WP, et al. Functional heterogeneity of anti-heparin platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Clin Appl Thromb Hemost. 1999;5(suppl 1):S32-S37.
14. Untch B, Ahmad S, Jeske WP, et al. Prevalence, isotype and functionality of anti-heparin-platelet factor 4 antibodies in patients clinically suspected for heparin-induced thrombocytopenia: the pathogenic role of IgG. Thromb Res. 2002; 105:117-123.
15. Ahmad S, Haas S, Hoppensteadt DA, et al. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Thromb Res. 2002;108:49-55.
16. Suh JS, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol. 1997; 54:196-201.
17. Brandt JT, Isenhart CE, Osborne JM, et al. On the role of platelet Fc gamma Rlla phenotype in heparin-induced thrombocytopenia. Thromb Haemost. 1995; 74:1564-1572.
18. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000;96:182-187.
19. Ahmad S, Iqbal O, Tobu M, Demir M. Immunobiology and pathophysiology of heparin-induced thrombocytopenia/thrombosis syndromean update. Turk J Haematol. 2002;19:127-131.
20. Jeske WP, Fareed J, Eschenfelder V, et al. Biochemical and pharmacologic characteristics of a low-molecular-mass heparin, reviparin. Semin Thromb Hemost. 1997;23:119-128.
21. Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med. 2001;344:626-631.
22. Haas S, Breyer H-G, Bacher HP, et al. Prevention of severe venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial). N Engl J Med. In press.
23. Kakkar VV, Hoppensteadt DA, Fareed J, et al. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood. 2002;99:1965-1970.
24. Ahmad S, Untch B, Moghaddam M, et al. Functional IgG subtype anti-heparin-PF4 antibodies is the principal mediator of HIT pathogenesis: clinical and diagnostic implications [abstract]. Blood. 2002;100:79b.
25. Lassen MR, Borris LC, Nakov RL. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. N Engl J Med. 2002;347:726-730.
26. Visentin GP, Moghaddam M, Beery SE, et al. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138:22-31.
27. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30.
28. Walenga JM, Jeske WP, Wood JJ, et al. Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin Hematol. 1999;36(suppl 1):22-28.
29. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
30. Lindhoff-Last E, Gerdsen F, Achermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2001;113:886-890.
31. Izban KF, Lietz HW, Hoppensteadt DA, et al. Comparison of two PF4/ heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost. 1999;25(suppl 1):51-56.
32. Aldabbagh A. Differential Pathogenic Profile of Anti-Heparin-PF4 Antibodies in Patients Treated With Unfractionated and Low-Molecular-Weight Heparins: Implications in the Management of Heparin-Induced Thrombocytopenia [master's thesis]. North Chicago, III: Finch University of Health Sciences/The Chicago Medical School; 2000.